Filippini Daria Maria, Broseghini Elisabetta, Carosi Francesca, Molin Davide Dal, Riefolo Mattia, Fabbri Laura, Abeshi Andi, Fernandez Ignacio Javier, Ferracin Manuela
Division of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, Università di Bologna, 40138 Bologna, Italy.
Diagnostics (Basel). 2023 Apr 20;13(8):1492. doi: 10.3390/diagnostics13081492.
Head and neck cancer of unknown primary (HNCUP) is defined as cervical lymph node metastases without a detectable primary tumor. The management of these patients presents a challenge to clinicians since guidelines in the diagnosis and treatment of HNCUP remain controversial. An accurate diagnostic workup is fundamental for the search for the hidden primary tumor to allow the best adequate treatment strategy. The purpose of this systematic review is to present the currently available data about the diagnostic and prognostic molecular biomarkers for HNCUP. Systematic research in an electronic database was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol and identified 704 articles, of which 23 studies were selected and included in the analysis. Fourteen studies investigated HNCUP diagnostic biomarkers and focused on the human papilloma virus (HPV) and the Epstein-Barr virus (EBV) due to the strong associations with oropharyngeal cancer and nasopharyngeal cancer, respectively. HPV status was shown to possess prognostic value, correlating with longer disease-free survival and overall survival. HPV and EBV are the only available HNCUP biomarkers, and they are already used in clinical practice. A better characterization of the molecular profiling and the development of tissue-of-origin classifiers are necessary to improve the diagnosis, staging, and therapeutic management of patients with HNCUP.
原发灶不明的头颈癌(HNCUP)定义为存在颈部淋巴结转移但未检测到原发肿瘤。这些患者的管理对临床医生来说是一项挑战,因为HNCUP的诊断和治疗指南仍存在争议。准确的诊断检查对于寻找隐匿的原发肿瘤以制定最佳的适当治疗策略至关重要。本系统评价的目的是呈现目前关于HNCUP诊断和预后分子生物标志物的可用数据。使用系统评价和Meta分析的首选报告项目(PRISMA)方案在电子数据库中进行了系统研究,共识别出704篇文章,其中23项研究被选中并纳入分析。14项研究调查了HNCUP诊断生物标志物,分别因与人乳头瘤病毒(HPV)和鼻咽癌、爱泼斯坦-巴尔病毒(EBV)与口咽癌有很强的关联而聚焦于它们。HPV状态显示具有预后价值,与更长的无病生存期和总生存期相关。HPV和EBV是仅有的可用HNCUP生物标志物,并且它们已在临床实践中使用。更好地描述分子谱特征以及开发组织起源分类器对于改善HNCUP患者的诊断、分期和治疗管理是必要的。